Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth

globenewswire.com
ABBV AbbVie is mentioned as a company featured in a report on the growing global cannabis pharmaceuticals market, indicating potential involvement or interest in the sector. ACB Aurora Cannabis is named as a company featured in a report on the expanding global cannabis pharmaceuticals market, indicating potential participation in this growth area. BHC Bausch Health is mentioned as a company featured in a report on the growing global cannabis pharmaceuticals market, suggesting potential interest or activity in this sector. CGC Canopy Growth is listed as a company featured in a report on the expanding global cannabis pharmaceuticals market, indicating potential involvement in this growing industry.

Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Cannabis Pharmaceuticals - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Cannabis Pharmaceuticals was estimated at US$4.7 Billion in 2025 and is projected to reach US$111.1 Billion by 2032, growing at a CAGR of 57.1% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Cannabis-based pharmaceuticals are emerging as a transformative segment within the global healthcare industry, driven by increasing scientific validation of cannabinoids for medical applications. The legalization of medical cannabis in numerous countries has fueled research and development (R&D) efforts, leading to the approval of cannabis-derived drugs for conditions such as epilepsy, multiple sclerosis, and chronic pain. Additionally, shifting regulatory frameworks and growing physician acceptance are paving the way for cannabis-based formulations to be integrated into mainstream healthcare.

What Are the Key Drivers Behind the Growth of the Cannabis Pharmaceuticals Market?

The growth in the cannabis pharmaceuticals market is driven by several factors, including expanding medical cannabis legalization, increased R&D investment, and growing patient demand for alternative treatments. Regulatory approvals for cannabis-based drugs in North America and Europe have legitimized the sector, encouraging pharmaceutical companies to develop new formulations. The opioid crisis has also contributed to the demand for non-addictive pain management solutions, positioning cannabis as a viable alternative.

Additionally, advancements in drug delivery systems and precision dosing are improving the efficacy of cannabis-based medications, further accelerating market growth. As global healthcare systems continue to recognize the benefits of medical cannabis, the pharmaceutical cannabis sector is poised for significant expansion.

How Are Advancements in Cannabis Research Expanding Pharmaceutical Applications?

Ongoing clinical research has uncovered the therapeutic potential of cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC), leading to the development of prescription cannabis-based drugs. Pharmaceutical companies are investing in cannabinoid extraction and formulation technologies to enhance bioavailability, stability, and targeted delivery.

Advances in nanotechnology and encapsulation methods are improving the efficacy of oral, transdermal, and inhalable cannabis medications. Additionally, the exploration of minor cannabinoids such as cannabigerol (CBG) and cannabinol (CBN) is expanding the therapeutic scope of cannabis pharmaceuticals, potentially leading to new treatments for neurodegenerative diseases, anxiety disorders, and autoimmune conditions.

Which Therapeutic Areas Are Driving the Demand for Cannabis Pharmaceuticals?

The primary demand for cannabis-based pharmaceuticals comes from patients suffering from chronic pain, neurological disorders, and mental health conditions. Epidiolex, a CBD-based drug, has gained FDA approval for treating rare forms of epilepsy, while Sativex, an oral spray containing THC and CBD, is widely used for multiple sclerosis-related spasticity.

The growing acceptance of cannabis for pain management is leading to its adoption as an alternative to opioids, particularly for cancer and arthritis patients. Additionally, ongoing research into cannabis-based treatments for anxiety, PTSD, and sleep disorders is expanding the potential applications of cannabis pharmaceuticals.

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 43 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.

Report Features:

Key Insights:

Report Scope

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

MARKET TRENDS & DRIVERS

FOCUS ON SELECT PLAYERS:Some of the companies featured in this Cannabis Pharmaceuticals market report

For more information about this report visit https://www.researchandmarkets.com/r/epug9o

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment